Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction...

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Syndrome

Background:

• Glucose-insulin-potassium infusions are standard for uncomplicated acute myocardial infarction (AMI).
• Efficacy is unproven in AMI with left ventricular (LV) dysfunction due to volume load concerns.
• Glucagon-like peptide-1 (GLP-1) stimulates glucose uptake without requiring glucose infusion.

Purpose of the Study:

• To investigate the safety and efficacy of GLP-1 infusion in patients with AMI and LV dysfunction.
• To compare outcomes in patients receiving GLP-1 plus standard therapy versus standard therapy alone.

Main Methods:

• A 72-hour infusion of GLP-1 (1.5 pmol/kg/min) was added to background therapy in 10 AMI patients with LV ejection fraction (EF) <40%.
• 11 control patients received only background therapy after primary angioplasty.
• Echocardiograms were used to assess LV ejection fraction and wall motion scores post-reperfusion and post-infusion.

Main Results:

• Both groups had severe baseline LV dysfunction (LVEF=29+/-2%).
• GLP-1 significantly improved LVEF (29+/-2% to 39+/-2%), global wall motion score index, and regional wall motion score index compared to controls.
• Benefits were observed regardless of AMI location or diabetes history. GLP-1 was well tolerated.

Conclusions:

• GLP-1 infusion, when added to standard therapy, enhances regional and global LV function in AMI patients with severe systolic dysfunction.
• GLP-1 represents a promising therapeutic option for improving cardiac function post-AMI in this vulnerable patient population.